EP1347745A2 - Diätmittel mit konjugierter linolsäure und calcium zur verbesserten gesundheit - Google Patents

Diätmittel mit konjugierter linolsäure und calcium zur verbesserten gesundheit

Info

Publication number
EP1347745A2
EP1347745A2 EP01998311A EP01998311A EP1347745A2 EP 1347745 A2 EP1347745 A2 EP 1347745A2 EP 01998311 A EP01998311 A EP 01998311A EP 01998311 A EP01998311 A EP 01998311A EP 1347745 A2 EP1347745 A2 EP 1347745A2
Authority
EP
European Patent Office
Prior art keywords
composition according
vitamin
mixture contains
mammal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01998311A
Other languages
English (en)
French (fr)
Other versions
EP1347745A4 (de
Inventor
Adrianne Bendich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1347745A2 publication Critical patent/EP1347745A2/de
Publication of EP1347745A4 publication Critical patent/EP1347745A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates generally to a dietary supplement, and more particularly, to an oral supplement.
  • Cardiovascular disease is generally recognized to be the primary killer of men and women in developed countries globally. The cost of these premature deaths is great both to the individuals and their families and to the health care system of the country as a whole.
  • the risk factors for cardiovascular disease are well-recognized and include: higher than average serum cholesterol, elevated levels of LDL; a low level of HDL in proportion to the LDL level; higher than average serum triglycerides; higher levels of lipid oxidation products creating plaques and streaks which cause blockages of coronary arteries.
  • Another CVD risk factor, high blood pressure is also a risk factor for strokes.
  • CLA conjugated linoleic acid
  • Vitamin E is the major lipid-soluble antioxidant in the human body [L. Mosca, et al, "Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease,” J Am Coll CardioL 30:392-9 (1997)].
  • Vitamin C is another well-known anti-oxidant. See A.
  • the present invention provides a novel composition which may be incorporated into an orally administered dietary supplement for the reduction of risk factors associated with CVD.
  • the dietary composition of the invention represents a unique combination of active dietary factors (essential nutrients and non-essential food components) that have never before been developed into a single supplement. This combination is surprisingly effective in the treatment of a variety of risk factors which have been linked to heart attacks, particularly reduction of overall serum cholesterol levels, reductions in high blood pressure, increase in the HDL:LDL ratio, reduction of triglycerides and homocysteine levels, and prevention of lipid oxidation and the formation of plaques and streaks.
  • the composition of this invention comprises the following dietary components: conjugated linoleic acid (CLA); vitamin E; vitamin C; docasahexanoic acid "DHA"; folic acid; vitamin B6 and vitamin B12, and calcium.
  • CLA conjugated linoleic acid
  • DHA docasahexanoic acid
  • folic acid vitamin B6 and vitamin B12, and calcium.
  • each of these components which independently reduce one or more of the risk factors for CVD, work synergistically to reduce the risk of CVD more effectively than any of these components taken alone. Additionally, all of the components have wide safety margins, therefore it is expected that the combination of all of these active components will require a lower concentration of each component alone, and therefore, enhance the safety of the combination of these dietary factors.
  • the invention provides a pharmaceutical and/ or dietary composition containing the formulation described above in admixture with pharmaceutically acceptable base, and optionally containing other known agents including, but not limited to stabilizer agents, preservatives and emulsifiers.
  • compositions, according to this invention may be presented in different embodiments, including but not limited to tablets, powders, chews, bars, and shakes or similar formulations.
  • a method for preparing the novel dietary compositions described herein and incorporating the same into orally administrated pharmaceutical compositions.
  • this invention provides a process for treating individuals to reduce the risk factors for CVD comprising orally administering a pharmaceutical composition as described above.
  • the present invention provides novel compositions comprised of combinations of selected mixtures of active dietary factors, including certain vitamins and other components, which are surprisingly effective in their ability to reduce the risk factors of CVD and promote improved cardiovascular health.
  • the oral administration of these compositions acts to reduce serum cholesterol levels and blood pressure, increase HDL levels in proportion to LDL levels, to protect lipids from oxidation thereby preventing the formation of plaques and streaks which block coronary arteries, and to lower both triglyceride levels and homocysteine levels.
  • oral administration of the compositions of this invention acts to reduce the risk of stroke, as well as heart attack, in human adults.
  • compositions of this invention include those dietary admixtures in which the formulations is swallowed in any acceptable form.
  • Conventional forms for this purpose include but are not limited to liquids, tablets, effervescent tablets, pills, powders, wafers or premixed shakes. See Remington's Practice of Pharmacy, 11 th Edition, (1956).
  • compositions of the present invention are comprised of the following vitamins and dietary factors which in combination provide a surprising result in reducing the risk factors of CVD.
  • the combination of dietary factors and vitamins work synergistically to improve cardiovascular health to a great degree than expected.
  • the essential components of the compositions are CLA, docosahexaenoic acid "DHA", vitamin E, vitamin C, folic acid, vitamin B6, vitamin B 12, and calcium.
  • the conjugated linoleic acid useful in the present invention refers to any member of a group of several variants of linoleic acid (also termed octadecadienoic acid).
  • CLA may be isolated from foods such as cheese and milk using methods known to those of skill in the art.
  • CLA may be synthesized using known techniques.
  • CLA may be synthesized from 95% pure linoleic acid [D. DeVoney et al, "Trans-10,Cis-12 Octadecadienoic acid increases lymphocyte proliferation", p. 56, 1998 Annual Report of the Food
  • Such synthesized CLA typically contains 43% c9, tl l/t9,cl 1
  • CLA may also be purchased from a variety of commercial sources, e.g., CLA enriched for c9,tl l/t9 applyingcl 1 (70.5% with no tl0,cl2 is available form Matreya, Inc); CLA may also be purchased from Peak Nutrition, Syracuse, NE.
  • CLA is present in the composition of the invention in an amount of about 250 mg to about 3000 mg; more desirably, about 300 mg to about 2000 mg, and most preferably, about 500 mg to about 1000 mg per dose.
  • CLA is contributes to the ability of the composition of the invention to protect against cancer, and to modulate the immune system.
  • the composition of the invention further includes vitamin E, which may be in any suitable form.
  • Natural vitamin E can be isolated from vegetable oils, including corn, cottonseed, rapeseed, peanut, sunflower and soybean oil, or obtained from a variety of commercial sources. Natural vitamin E may be in the form d- alpha-tocopherol (RRR-alpha-tocopherol), or the acetate [d-alpha-tocopheryl acetate (RRR-alpha-tocopheryl acetate)] or succinate salt thereof [d-alpha-tocopheryl acid succinate (RRR-alpha-tocopheryl acid succinate)], or may be in the form of natural mixed tocopherols [d-alpha-, d-beta-, d-gamma and d-delta-tocopherol].
  • synthetic vitamin E may be produced from petrochemicals in the form of dl-alpha-tocopherol ( all-rac-alpha-tocopherol), or the acetate [dl-alpha- tocopheryl acetate, (all-rac-alpha-tocopheryl acetate)] or succinate salt thereof [dl- alpha-tocopheryl acid succinate (all-rac-alpha-tocopheryl acid succinate), or mixtures thereof.
  • any of the natural or synthetic forms of the vitamin may be used, or combinations thereof.
  • Vitamin E prevents the blockage of coronary arteries and other vessels within the body that result when oxidized lipids are permitted to form [S.B.
  • vitamin E is a useful as an antioxidant [Jeng et al, Am. J. Clin. Nutr.. 64:960-5 (1996); F.M. Steinberg and A. Chait, Am. J. Clin. Nutr.. 68:319-27 (1998), [publ. erratum appears in Am J Clin Nutr., Jun:69(6):1293 (1999)]
  • the composition of the invention contains about 50 IU to about 800 IU of vitamin E, and most preferably, about 100 IU.
  • Vitamin C is another component of the composition of the invention.
  • Vitamin C is an anti-oxidant which works synergistically with Vitamin E to protect cellular components from oxidative damage leading to cardiovascular disease.
  • Vitamin C optimizes the effects of Vitamin E to reduce the oxidation of lipids.
  • Vitamin C taken alone has been linked with a decreased risk of CVD as well as CVD mortality, possibly because of the reduction in systolic and diastolic blood pressure seen in those individuals taking large does of the vitamin [S.J. Duffy et al, "Treatment of hypertension with ascorbic acid", Lancet. 354:2048-9 (1999); P. Weber et al, "Vitamin C and human health - a review of recent data relevant to human requirements", Int.
  • vitamin C is in the form of ascorbate or ascorbic acid, and is present in an amount of about 60 mg to about 1000 mg, or about 100 to about 500 mg.
  • the present invention further includes an omega-3 fatty acid which is known to cause reduction in triglycerides and increase in HDL levels. Most preferably, this omega-3 fatty acid is in the form of docasahexaenoic acid "DHA", which may be extracted from algae using known methods or purchased commercially. DHA is the longest omega-3 fatty acid and is known to be important in the functioning of every cell membrane in the body. It is found in especially high concentration in the human brain and retina.
  • DHA docasahexaenoic acid
  • the composition of the invention contains about 125 mg to about 500 mg, and preferably about 230 to about 250 mg DHA.
  • another omega-3 oil may be included in the composition of the invention.
  • the composition of the invention contains about 400 ⁇ g to about 1000 ⁇ g folic acid (or folate); about 2 mg to about 50 mg vitamin B6, preferably about 10 to 25 mg vitamin B6; and about 6 ⁇ g to about 1 mg vitamin B 12.
  • composition of this invention contains about 200 to about 100 mg of elemental calcium, which may be in the form of pharmaceutically acceptable salt thereof. In one desirable embodiment, calcium is present in the composition of the form of calcium carbonate.
  • the eight active components discussed above may be admixed with other active ingredients.
  • these components are the only active ingredients in the composition of the invention.
  • Example 1 One particularly desirable embodiment of the composition of the invention is provided in Example 1 below.
  • the invention is not limited by this formulation, or by the ranges provided herein, which are intended for guidance only.
  • One of skill in the art can readily select other ranges, depending upon the delivery form (e.g., effervescent tablet vs. tablet), the age, and condition of the patient, among other factors.
  • a composition of the formulation of the invention may be used orally to treat and/or prevent risk factors of CVD and stroke, including reduction of high blood pressure and overall serum cholesterol.
  • compositions work by acting at different sites and aspects of cardiovascular disease.
  • High cholesterol, high LDL, elevated triglycerides, high blood pressure, low HDL, high homocysteine levels and oxidized lipids are all attacked by one or more of the dietary factors present in the oral formulation and act synergistically to reduce the risk factors of CVD.
  • CVD risk factors By affecting CVD risk factors at several sites and by different mechanisms of action, there is an enhancement of the effects of the supplement that is greater than the additive effect of the dietary factors.
  • the dietary supplement contains active ingredients that are safe, efficacious and cost-effective in lowering CVD risk factors.
  • compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.
  • unit dosage forms such as tablets, capsules, pills, powders, granules, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.
  • oral administration either solid or fluid unit dosage forms can be prepared.
  • Powders are prepared quite simply by comminuting the active ingredient(s) to a suitably fine size and mixing with a similarly comminuted diluent.
  • the diluent can be an edible carbohydrate material such as lactose or starch.
  • a sweetening agent or sugar is present as well as a flavoring oil.
  • Capsules are produced by preparing a powder mixture as hereinbefore described and filling into formed gelatin sheaths.
  • a lubricant such as a talc, magnesium stearate, and the like is added to the powder mixture before the filling operation.
  • Soft gelatin capsules are prepared by machine encapsulation of a slurry of active ingredients with an acceptable vegetable oil, light liquid petrolatum or other inert oil or triglyceride.
  • Tablets, chews and bars are made by preparing a powder mixture, granulating or slugging, adding a lubricant and pressing into tablets, chews, or bars.
  • the powder mixture is prepared by mixing an active ingredient, suitably comminuted, with a diluent or base such as starch, lactose, kaolin, dicalcium phosphate and the like.
  • the powder mixture can be granulated by wetting with a binder such as corn syrup, gelatin solution, methylcellulose solution or acacia mucilage and forcing through a screen.
  • the powder mixture can be slugged, e.g., run through the tablet, bar or chew, machine and the resulting imperfectly formed tablets broken into pieces (slugs).
  • the slugs can be lubricated to prevent sticking to the shape-forming dies by means of the addition of stearic acid, a stearic salt, talc or mineral oil.
  • the lubricated mixture is then compressed into tablets, chews or bars, as desired.
  • a tablet can be provided with a protective coating consisting of a sealing coat or enteric coat of shellac, a coating of sugar and methylcellulose and polish coating of carnauba wax.
  • chews and bars may be mixing with a variety of flavorings, sweetening agents, or the like.
  • Fluid unit dosage forms for oral administration such as syrups, elixirs and suspensions can be prepared wherein each teaspoonful of composition contains a predetermined amount of active ingredient for administration.
  • the water-soluble forms can be dissolved in an aqueous vehicle together with sugar, flavoring agents and preservatives to form a syrup.
  • An elixir is prepared by using a hydroalcoholic vehicle with suitable sweeteners together with a flavoring agent.
  • Suspensions can be prepared on the insoluble forms with a suitable vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.
  • the invention provides a method of using the composition to improve the health of the heart and to reduce risk factors associated with cardiovascular disease by delivering to an individual the composition of the invention.
  • delivery of the composition of the invention e.g., by oral administration, is useful for preventing oxidation of low density lipoprotein (LDL), increasing high density lipoprotein (HDL), and for reducing total cholesterol.
  • Delivery of the composition of the invention is also useful for reducing triglycerides and reducing homocysteine.
  • compositions of the invention are formulated such that an effective amount is delivered by two tablets (or other suitable formulation) a day.
  • these doses may be taken with meals, mixed into feed, or taken on an empty stomach.
  • improvement is observed after two weeks of daily use.
  • Several factors have been observed to interfere with the positive effects of dietary supplementation with the compositions of the invention, including smoking, eating a high fat diet, omitting dietary fibers or roughage from a daily diet and maintaining an essentially sedentary lifestyle.
  • the compositions of the present invention in addition to their use in treating CVD in humans, may also be useful in treating non-human animals, particularly mammals.
  • these dietary supplements may be useful for companion animals such as dogs and cats, for cattle, horses, and pigs, among other animals.
  • companion animals such as dogs and cats
  • cattle, horses, and pigs among other animals.
  • the following example which demonstrates the compositions of the invention for illustrative purposes only and does not limit the scope of the invention.
  • the compositions of this invention are anticipated to produce surprisingly good results in reducing a variety of risk factors associated with impaired cardiovascular conditions.
  • the compositions of the invention have advantages over the prior art in safely lowering CVD risk factors in a cost effective manner.
  • the components listed below were combined into a tablet, using simple mixing procedures.
  • ingredients all or in part can be: 1. Mixed dried (direct compression process-DCP) with well recognized tableting aid(s)/f ⁇ ller(s), binding agent(s), disintegrant (s) and lubricant(s), as necessary or desired to form a blend that can be directly compressed into tablets; or
  • Wet granulated (Wet Granulation Process-WGP) with well recognized tableting aid(s)/filler(s), granulating agent(s), disintegrant(s) and lubricant(s) as necessary or desired to form a blend that it can be directly compressed into tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP01998311A 2000-11-29 2001-11-29 Diätmittel mit konjugierter linolsäure und calcium zur verbesserten gesundheit Withdrawn EP1347745A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25389700P 2000-11-29 2000-11-29
US253897P 2000-11-29
PCT/US2001/044872 WO2002043662A2 (en) 2000-11-29 2001-11-29 Dietary composition containing conjugated linoleic acid and calcium for improved health

Publications (2)

Publication Number Publication Date
EP1347745A2 true EP1347745A2 (de) 2003-10-01
EP1347745A4 EP1347745A4 (de) 2007-10-17

Family

ID=22962148

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01998311A Withdrawn EP1347745A4 (de) 2000-11-29 2001-11-29 Diätmittel mit konjugierter linolsäure und calcium zur verbesserten gesundheit

Country Status (6)

Country Link
EP (1) EP1347745A4 (de)
JP (1) JP2004514685A (de)
AU (1) AU2002219949A1 (de)
CA (1) CA2427681A1 (de)
MX (1) MXPA03004817A (de)
WO (1) WO2002043662A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US6743931B2 (en) * 2002-09-24 2004-06-01 Natural Asa Conjugated linoleic acid compositions
FR2847472B1 (fr) * 2002-11-22 2006-08-11 Synergia Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires
ITMI20030903A1 (it) * 2003-05-05 2004-11-06 Dietetic S P A Composizioni utili per il controllo del peso.
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
EP2014180A1 (de) 2007-07-08 2009-01-14 Barilla G. e R. Fratelli S.p.A. Zusammensetzung zur Reduktion von Herz-Kreislauf-Risiken und Nahrungsmittel damit

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066133A1 (en) * 1999-05-03 2000-11-09 Drugtech Corporation Dietary supplement
WO2001024772A1 (en) * 1999-09-30 2001-04-12 Drugtech Corporation Formulation for menopausal women

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066133A1 (en) * 1999-05-03 2000-11-09 Drugtech Corporation Dietary supplement
WO2001024772A1 (en) * 1999-09-30 2001-04-12 Drugtech Corporation Formulation for menopausal women

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0243662A2 *

Also Published As

Publication number Publication date
WO2002043662A3 (en) 2003-01-23
JP2004514685A (ja) 2004-05-20
AU2002219949A1 (en) 2002-06-11
MXPA03004817A (es) 2003-09-10
CA2427681A1 (en) 2002-06-06
EP1347745A4 (de) 2007-10-17
WO2002043662A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
US20040018248A1 (en) Composition containing statins and calcium for improved cardiovascular health
US20060105033A1 (en) Dietary composition containing conjugated linoleic acid and calcium for improved health
CA2427618A1 (en) Composition containing statins and calcium for improved cardiovascular health
US5364644A (en) Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders
CA2229624C (en) Method of reducing bodyweight and treating obesity
AU778507B2 (en) Formulation for menopausal women
AU780504B2 (en) Nutritional supplements
EP2301530A1 (de) Verwendung einer Fettsäurezusammensetzung mit einer Kombination aus EPA und DHA zur Reduktion des Körpergewichts
MXPA06013676A (es) Formulaciones nutricionales.
US6020383A (en) Method for reducing blood cholesterol and/or blood triglycerides
US20170020834A1 (en) Prophylactic use of neuroprotectants in sports-related traumatic brain injury
WO2002043662A2 (en) Dietary composition containing conjugated linoleic acid and calcium for improved health
KR100270622B1 (ko) 영양보급용 영양 조성물
EP1617734A1 (de) Multivitamin- und mineralstoffergänzung für schwangere
US20130064924A1 (en) Nutritional supplement for use under physiologically stressful conditions
JP2002360220A (ja) 血行障害の改善作用を有する健康補助食品
JP4997514B2 (ja) 血圧上昇抑制剤
RU2351350C1 (ru) Набор "предстар", его применение и способ предупреждения преждевременного старения организма
US9308261B2 (en) Compositions and methods for treating varicose veins
CA2492417C (en) Formulation for menopausal women
MXPA01007008A (es) Metodo para reducir colesterol en sangre y/o trigliceridos en sangre

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030624

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20070913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071213